Mifepristone
-
Subject Areas on Research
- 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity.
- Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment.
- Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor.
- Effects of progesterone and estradiol sex hormones on the release of microparticles by RAW 264.7 macrophages stimulated by Poly(I:C).
- Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
- Endocrine therapy in metastatic breast cancer.
- Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis.
- Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo.
- Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins.
- Identification of a negative regulatory function for steroid receptors.
- Insulin inhibits dexamethasone effect on angiotensinogen gene expression and induction of hypertrophy in rat kidney proximal tubular cells in high glucose.
- Ligand-specific dynamics of the androgen receptor at its response element in living cells.
- Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs).
- Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer.
- Mifepristone (RU 486) for Alzheimer's disease.
- Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.
- Peptide antagonists of the human estrogen receptor.
- Phenotypic consequences of lung-specific inducible expression of FGF-3.
- RU486 blocks the anti-inflammatory effects of exercise in a murine model of allergen-induced pulmonary inflammation.
- RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism.
- RU486 in depression.
- Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells.
- The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins.
- The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.
- The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity.
- The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor.
- The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.
- The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.
-
Keywords of People
- McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Duke Innovation & Entrepreneurship